Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Drug

Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments

Fineline Cube Aug 16, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US...

Company

Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending

Fineline Cube Aug 16, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...

Company Deals

Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal

Fineline Cube Aug 16, 2023

Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...

Company Drug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Fineline Cube Aug 16, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...

Company Deals

Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies

Fineline Cube Aug 16, 2023

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

Fineline Cube Aug 16, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...

Company Drug

YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment

Fineline Cube Aug 16, 2023

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...

Company Drug

Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam

Fineline Cube Aug 16, 2023

China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...

Company

CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones

Fineline Cube Aug 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...

Company Deals

HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research

Fineline Cube Aug 15, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...

Company Drug

Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication

Fineline Cube Aug 15, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence

Fineline Cube Aug 15, 2023

Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy

Fineline Cube Aug 15, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...

Company Deals

Jiangsu Hengrui Pharmaceuticals Strikes Licensing Deal with One Bio Inc. for TSLP-Targeted mAb SHR1905

Fineline Cube Aug 15, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with...

Company Drug

J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment

Fineline Cube Aug 15, 2023

The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...

Company Drug

Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial

Fineline Cube Aug 15, 2023

Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...

Company Deals

AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant

Fineline Cube Aug 15, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) is set to invest an additional USD 250...

Company Deals

Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio

Fineline Cube Aug 15, 2023

Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...

Policy / Regulatory

NHC Addresses Anti-Corruption Efforts in Pharmaceutical Industry Nationwide

Fineline Cube Aug 15, 2023

The National Health Commission (NHC) convened a conference to address questions on the ongoing anti-corruption...

Company Drug

Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 15, 2023

This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...

Posts pagination

1 … 430 431 432 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.